ArticlemAbs2025

A bispecific antibody-drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia.

Hollie B S Griffiths et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.